全文获取类型
收费全文 | 28376篇 |
免费 | 2323篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 126篇 |
儿科学 | 1036篇 |
妇产科学 | 848篇 |
基础医学 | 3785篇 |
口腔科学 | 433篇 |
临床医学 | 3805篇 |
内科学 | 5229篇 |
皮肤病学 | 353篇 |
神经病学 | 3184篇 |
特种医学 | 661篇 |
外科学 | 3011篇 |
综合类 | 491篇 |
一般理论 | 52篇 |
预防医学 | 3615篇 |
眼科学 | 441篇 |
药学 | 1831篇 |
中国医学 | 34篇 |
肿瘤学 | 1824篇 |
出版年
2023年 | 213篇 |
2022年 | 249篇 |
2021年 | 572篇 |
2020年 | 417篇 |
2019年 | 650篇 |
2018年 | 721篇 |
2017年 | 556篇 |
2016年 | 582篇 |
2015年 | 641篇 |
2014年 | 908篇 |
2013年 | 1380篇 |
2012年 | 1937篇 |
2011年 | 2034篇 |
2010年 | 1098篇 |
2009年 | 1001篇 |
2008年 | 1643篇 |
2007年 | 1814篇 |
2006年 | 1820篇 |
2005年 | 1658篇 |
2004年 | 1671篇 |
2003年 | 1511篇 |
2002年 | 1427篇 |
2001年 | 425篇 |
2000年 | 376篇 |
1999年 | 381篇 |
1998年 | 320篇 |
1997年 | 276篇 |
1996年 | 224篇 |
1995年 | 189篇 |
1994年 | 168篇 |
1993年 | 191篇 |
1992年 | 258篇 |
1991年 | 263篇 |
1990年 | 229篇 |
1989年 | 223篇 |
1988年 | 168篇 |
1987年 | 179篇 |
1986年 | 157篇 |
1985年 | 177篇 |
1984年 | 149篇 |
1983年 | 151篇 |
1982年 | 128篇 |
1981年 | 111篇 |
1980年 | 114篇 |
1979年 | 113篇 |
1978年 | 103篇 |
1977年 | 81篇 |
1976年 | 81篇 |
1974年 | 83篇 |
1973年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
1.
2.
3.
4.
5.
6.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
7.
Martina A. Steurer Jean Costello Rebecca J. Baer Scott P. Oltman Sky K. Feuer Tania Pacheco-Werner Elizabeth Rogers Marta M. Jankowska Jessica Block Molly McCarthy Matthew S. Pantell Christina Chambers Kelli K. Ryckman Laura L. Jelliffe-Pawlowski 《Paediatric and perinatal epidemiology》2020,34(2):130-138
8.
Béla Nagy Zsolt Bene Zsolt Fejes Sonya L. Heltshe David Reid Nicola J. Ronan Yvonne McCarthy Daniel Smith Attila Nagy Elizabeth Joseloff György Balla János Kappelmayer Milan Macek Scott C. Bell Barry J. Plant Margarida D. Amaral István Balogh 《Journal of cystic fibrosis》2019,18(2):271-277
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献9.
Mary Ann Richardson Helen M Chao Laura L Read James D Clelland Raymond F Suckow 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2006,(2):195-197
Phenylketonuria (PKU), an inborn error of phenylalanine metabolism, has been shown to be a risk factor for tardive dyskinesia (TD). In male psychiatric patients there was a significant relationship between TD and measures of plasma phenylalanine following ingestion of a standardized phenylalanine dose that was indicative of higher brain availability of phenylalanine in patients with TD. In addition, a medical food formulation consisting of branched chain amino acids, which compete with phenylalanine for transport across the blood-brain barrier, has been demonstrated to be an efficacious treatment for TD. Cumulatively these findings suggested that TD was related to phenylalanine metabolism and thus that sequence variants in the gene for phenylalanine hydroxylase (PAH), the rate-limiting enzyme in the catabolism of phenylalanine, could be associated with TD susceptibility. Genetic screening of PAH in a group of 123 psychiatric patients revealed ten sequence polymorphisms and two mutations, but none appeared to be a significant risk factor for TD. 相似文献
10.